ArticleMicrobial biotechnology2026
Identification and Characterisation of the Gene Cluster Governing Biosynthesis of the Anti-Mycobacterial Antibiotic Acidomycin.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Acidomycin is an anti-mycobacterial antibiotic with a unique mode of action, targeting the biotin biosynthesis pathway. Despite being highly active against mycobacteria in vitro, its development as an anti-tubercular agent has been hindered due to suboptimal pharmacokinetics. Engineering of the acidomycin biosynthesis may yield new analogues with improved pharmacological properties. Here, we describe the identification of the acidomycin biosynthetic gene cluster (BGC) in a Streptomyces bacterium isolated from the rhizosphere of Edelweiss. Notably, the acidomycin BGC is located in proximity to the genes for the biosynthesis of stravidins, secondary metabolites targeting a different enzyme in the biotin biosynthesis pathway, and two genes for streptavidins, proteins that strongly bind and sequester biotin. The identity of the acidomycin BGC was confirmed via both gene knock-out and heterologous expression, which suggested that the fatty acid required for the formation of acidomycin's acyl chain is most likely scavenged from the biotin biosynthesis pathway. CRISPR/Cas9-assisted knock-out of the cytochrome P450-encoding gene in the acidomycin BGC resulted in a significant decrease in its yield but did not abrogate the biosynthesis completely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.